Rice Hall James & Associates LLC Reduces Position in iRadimed Corporation $IRMD

Rice Hall James & Associates LLC trimmed its stake in iRadimed Corporation (NASDAQ:IRMD) by 31.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,593 shares of the medical equipment provider’s stock after selling 20,429 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.34% of iRadimed worth $3,102,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Nuveen LLC purchased a new position in shares of iRadimed during the first quarter valued at approximately $1,418,000. American Century Companies Inc. raised its holdings in iRadimed by 13.8% in the 1st quarter. American Century Companies Inc. now owns 18,284 shares of the medical equipment provider’s stock valued at $960,000 after acquiring an additional 2,213 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of iRadimed by 38.2% during the 1st quarter. Voya Investment Management LLC now owns 11,711 shares of the medical equipment provider’s stock worth $615,000 after purchasing an additional 3,239 shares during the period. Ranger Investment Management L.P. lifted its stake in shares of iRadimed by 7.4% during the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after purchasing an additional 14,730 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in shares of iRadimed by 10.9% during the first quarter. Acadian Asset Management LLC now owns 156,319 shares of the medical equipment provider’s stock worth $8,197,000 after purchasing an additional 15,329 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the subject of several analyst reports. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 22nd. Lake Street Capital reissued a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Finally, Roth Capital set a $90.00 price target on shares of iRadimed in a research report on Friday, October 31st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.33.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $96.73, for a total transaction of $483,650.00. Following the completion of the sale, the chief executive officer directly owned 2,287,500 shares of the company’s stock, valued at approximately $221,269,875. This represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John Glenn sold 15,000 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the sale, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 65,000 shares of company stock worth $5,548,150 in the last 90 days. Company insiders own 36.80% of the company’s stock.

iRadimed Price Performance

iRadimed stock opened at $97.45 on Friday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of 59.06 and a beta of 1.06. iRadimed Corporation has a 12 month low of $47.48 and a 12 month high of $98.44. The stock’s 50-day moving average is $88.72 and its 200-day moving average is $74.24.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The business had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Research analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The firm also recently announced a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.